Current Medical Research and Opinion

Journal Information
ISSN / EISSN : 03007995 / 14734877
Current Publisher: Informa UK Limited (10.1080)
Former Publisher: Informa Healthcare (10.3111) , Informa Healthcare (10.1185)
Total articles ≅ 6,938
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
LOCKSS
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Shuling Li, Yi Peng, Jiannong Liu, Suying Li, Leon Raskin, Michael A. Kelsh, Rebecca Zaha, Prasad L. Gawade, David Henry, Gary H. Lyman
Current Medical Research and Opinion pp 1-9; doi:10.1080/03007995.2020.1801403

The publisher has not yet granted permission to display this abstract.
Arielle G. Bensimon, Yichen Zhong, Umang Swami, Allison Briggs, Joshua Young, Yuan Feng, Yan Song, James Signorovitch, Oluwakayode Adejoro, Abhiroop Chakravarty, et al.
Current Medical Research and Opinion pp 1-11; doi:10.1080/03007995.2020.1799771

Abstract:
Objective: Pembrolizumab/axitinib significantly prolonged overall survival (OS) and progression-free survival (PFS) and increased objective response rate versus sunitinib in the phase III trial KEYNOTE-426 among previously untreated patients with advanced renal cell carcinoma (RCC). This study assessed the cost-effectiveness of pembrolizumab/axitinib versus other first-line treatments of advanced RCC from a US public healthcare payer perspective. Methods: A partitioned survival model with three states (progression-free, progressed, death) evaluated lifetime costs and quality-adjusted life-years (QALYs) for pembrolizumab/axitinib and other first-line regimens: sunitinib, pazopanib, and avelumab/axitinib in the overall population; and sunitinib, cabozantinib, and nivolumab/ipilimumab in the subgroup with intermediate/poor prognostic risk. Costs of treatments, adverse events, and medical resources were estimated. OS, PFS, and treatment duration were extrapolated using parametric models fitted to KEYNOTE-426 data and hazard ratios from network meta-analyses. Utilities were derived through mixed-effects regressions of KEYNOTE-426 EuroQol-5 Dimensions-3 Levels data. Results: In the overall population, pembrolizumab/axitinib was associated with incremental cost-effectiveness ratios (ICERs) of $95,725/QALY versus sunitinib and $128,210/QALY versus pazopanib, and was dominant (lower cost, higher effectiveness) versus avelumab/axitinib, with incremental QALY gains of 2.73, 2.40, and 1.80 versus these therapies, respectively. In the intermediate/poor-risk subgroup, base-case ICERs for pembrolizumab/axitinib were $101,030/QALY versus sunitinib, $6,989/QALY versus cabozantinib, and $130,934/QALY versus nivolumab/ipilimumab, with incremental QALY gains of 2.62, 1.78, and 1.06 versus these therapies. Conclusions: In this economic evaluation, pembrolizumab/axitinib was associated with higher life expectancy and QALYs and, based on typical willingness-to-pay thresholds of $150,000-$180,000/QALY, was found cost-effective versus other first-line treatments for advanced RCC in the US.
C. Neill Epperson, Ming-Yi Huang, Keziah Cook, Deepshekhar Gupta, Anita Chawla, Paul E. Greenberg, Adi Eldar-Lissai
Current Medical Research and Opinion pp 1-10; doi:10.1080/03007995.2020.1799772

Abstract:
Objective: To quantify the economic burden of postpartum depression (PPD) that accrues to commercially insured households in the year following childbirth. Methods: Administrative claims data from OptumHealth Care Solutions (2009-2016) were used to identify households that included women identified with PPD per the algorithm and propensity score–matched comparison households of women who were not identified with PPD or a history of depression after childbirth. Study outcomes included direct total all-cause medical and pharmaceutical costs during the first year following childbirth and number of outpatient visits at the household level stratified by household member. Results: Households affected by PPD as identified by the algorithm (N = 7,769) incurred 22% higher mean total all-cause medical and pharmaceutical spending than unaffected matched controls (N = 41,308) during the first year following childbirth ($36,049 versus $29,448, P 50%) of total all-cause spending. Mothers identified with PPD had significantly higher annual mean direct total all-cause medical and pharmaceutical spending than their matched controls without PPD ($19,611 versus $15,410, P
Xiaohui Zhao, Sandipan Bhattacharjee, Kim Innes, Traci J. Lemasters, Nilanjana Dwibedi, Usha Sambamoorthi
Current Medical Research and Opinion pp 1-8; doi:10.1080/03007995.2020.1790345

The publisher has not yet granted permission to display this abstract.
Maria Antonia Pou, Raquel Gayarre, Alex Prada-Ojeda, Cesar Díaz-Torné
Current Medical Research and Opinion pp 1-2; doi:10.1080/03007995.2020.1799774

Sonya C. Tang Girdwood, Mark E. Murphy, Jennifer M. Kaplan
Current Medical Research and Opinion pp 1-3; doi:10.1080/03007995.2020.1799773

Michelle Heraughty, Colette Ridehalgh
Current Medical Research and Opinion pp 1-12; doi:10.1080/03007995.2020.1790349

The publisher has not yet granted permission to display this abstract.
Xin Yi Wong, Andrew Qi Jun Lim, Qian Yu Shen, John Whay Kuang Chia, Min Hoe Chew, Wah Siew Tan, Hwee-Lin Wee
Current Medical Research and Opinion pp 1-10; doi:10.1080/03007995.2020.1790348

The publisher has not yet granted permission to display this abstract.
Darko Mitrovic, Richard Folkeringa, Nic Veeger, Eric Van Roon
Current Medical Research and Opinion pp 1-6; doi:10.1080/03007995.2020.1786808

The publisher has not yet granted permission to display this abstract.
Back to Top Top